Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAddition Consistent secondary endpoint results, including PSA...
PluvictoTM demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
